Lung ventilation impairment in asthma patients with obesity

Yu. I. Feshchenko¹,1,A,F, G. L. Gumeniuk¹,2,A,D, M. I. Gumeniuk¹,C,D,E, S. V. Zaikov²,E, O. M. Rekalova¹,A,E, S. H. Opimakh¹,B,D

¹SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv, ²National Medical Academy of Postgraduate Education named after P. L. Shupyk, Kyiv, Ukraine

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

BA is characterized by more severe course, worse response to standard therapy in obese patients, therefore asthma with obesity is considered not just as comorbidity but as a distinct BA phenotype.

**Aim.** To study the lung ventilation impairment in asthma patients with obesity using capnometry. The tasks are to study parameters of lung ventilation in asthma patients and healthy persons and to compare these parameters in asthma patients depending on the presence of obesity.

**Materials and methods.** The study involved 60 participants (29 men and 31 women) aged 24 to 74 years, the mean age was 52.3 ± 2.7 years, including 30 patients with asthma and 30 healthy subjects. For all participants, body plethysmography and capnometry were performed.

**Results.** The respiratory minute volume and alveolar ventilation volume were higher in asthma patients with obesity, and the volume of dead space ventilation and its fraction in the tidal volume were not substantially different among the groups of patients with BA. Specifically in relation to the gas exchange parameters, it was found that in obese asthmatics, the end-tidal carbon dioxide pressure was significantly increased – 4.8 ± 0.1 kPa compared with non-obese patients 4.3 ± 0.1 kPa, P < 0.05. The end-tidal oxygen concentration was significantly decreased – 15.3 ± 0.2 % compared to normal weight patients 16.0 ± 0.2 %, P < 0.05.

**Conclusions.** Asthma patients with obesity have characteristics that include reduced total lung capacity, inspiratory capacity and forced vital capacity with a higher degree of airways obstruction. These changes lead to lung ventilation impairment with a tendency to carbon dioxide retention, which may be an unfavorable factor for the process of gas exchange with increased oxygen demands for the entire organism in obesity.

**Key words:** asthma, obesity, capnometry.

Zaporozhye medical journal 2019; 21 (6), 733–738
DOI: 10.14739/2310-1210.2019.6.186486

*E-mail: admin@ifp.kiev.ua

Original research

**Keywords:**

- asthma
- obesity
- capnometry

Zaporozhsky medical journal. – 2019. – Т. 21, № 6(117). – С. 733–738
We study the possibilities of capnometry in evaluating pulmonary ventilation in patients with asthma. Capnometry is a measurement and a digital representation of the concentration or partial pressure of carbon dioxide in the air that inhales or exhales the patient during the respiratory cycle. Due to the integration of capnometers and pneumotachometers in one device and the unique capnometry capability to calculate CO₂-free air during exhalation as a dead space volume and its fraction in the tidal volume, it is possible to evaluate the effectiveness of alveolar ventilation [7].

Materials and methods

The study involved 60 participants (29 men and 31 women) aged 24 to 74 years, the mean age was 52.3 ± 2.7 years including 30 patients with asthma and 30 healthy subjects.

The inclusion criteria for asthma patients – women and men from 18 years old, bronchial reversibility – percentage change in baseline forced expiratory volume in the first second (FEV1) of >12 % (or ≥200 ml) after administering short-acting β₂-agonists. Only asthma patients who had no signs of disease exacerbation at the time of the examination participated in the study. The inclusion criteria for healthy individuals – women and men from 18 years old with normal respiratory function without bronchial obstructive pathology at the time of the examination. In addition, for all participants – study protocol awareness and signed informed consent to participate in the study, the ability to understand and perform maneuvers of the diagnostic procedures.

The exclusion criteria were having other than asthma respiratory diseases, severe uncontrolled progressive chronic diseases that can affect the examination results, mental disorders.

The diagnosis of asthma was determined by the Order of Ministry of Health of Ukraine No 868 from 08.10.2013 “About the approval and implementation of medical-technological documents on the standardization of medical care for bronchial asthma” [8].

Body mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared. Obesity was defined in subjects with BMI 30.0 kg/m² or higher.

The BA group consisted of 30 patients (11 men and 19 women) with the mean age of 57.3 ± 2.3 years and the mean FEV₁, 72.3 ± 1.8 % with both normal weight and obesity.

The group of healthy individuals consisted of 30 subjects (18 men and 12 women) with the mean age of 48.7 ± 3.7 years and the mean FEV₁, 100.2 ± 1.5 % with normal weight.

Pulmonary function tests and capnometry were performed for all subjects.

The study was conducted at the Department of Respiratory Medicine, National Medical University named after I.P. Pavlova, Kyiv, Ukraine. Our study was approved and implemented by the Ministry of Health of Ukraine No 868 from 08.10.2013 “About the approval and implementation of medical-technological documents on the standardization of medical care for bronchial asthma” [8].

The prevalence of both obesity and bronchial asthma (BA) is increasing now as well as their comorbidity [1]. The problem of asthma and obesity has been studied since 1999, when it was found that overweight people have a higher risk of asthma development. After 10 years, the results of more than 50 studies worldwide have shown a higher incidence of asthma in obese individuals. Later, a causal relationship between weight gain and asthma development was proved [2].

In GINA (Global Initiative for Asthma) guidelines, obesity is included in the list of the risk factors and clinical manifestations of asthma. Weight reduction in obese and overweight patients with asthma is recommended in order to improve lung function, symptoms and health status. BA is characterized by more severe course, worse response to standard therapy in obese patients, therefore asthma with obesity is considered not just as a comorbidity but as a distinct BA phenotype [3].

Obesity is a state of the systemic inflammatory response, and fatty tissue is an active source of proinflammatory mediators (adipokines) secretion such as C-reactive protein, tumor necrosis factor α, interleukin-6, -4, -5 and -13, plasminogen activator inhibitor, eotaxin, vascular endothelial growth factor, monocyte chemotactic protein-1. Obesity is accompanied by oxidative stress, as evidenced by the increase in isoprostane-8 and other markers in both plasma and bronchiolar alveolar lavage fluid with increasing body mass index [4,5].

Obesity has a significant pathophysiological impact on the respiratory system function including ventilation, respiratory mechanics, respiratory muscle strength and endurance, gas exchange, control of respiration, decreasing exercise capacity and resulting in respiratory failure [6].

Repeated episodes of airway obstruction in asthma also lead to gas exchange disturbances especially due to ventilation-perfusion mismatch. The presence of significant gas exchange abnormalities along with almost normal clinical spirometric parameters in patients is the peculiarity of asthma [7].

We study the possibilities of capnometry in evaluating pulmonary ventilation in patients with asthma. Capnometry is a measurement and a digital representation of the concentration or partial pressure of carbon dioxide in the air that inhales or exhales the patient during the respiratory cycle. Due to the integration of capnometers and pneumotachometers in one device and the unique capnometry capability to calculate CO₂-free air during exhalation as a dead space volume and its fraction in the tidal volume, it is possible to evaluate the effectiveness of alveolar ventilation [7].

Aim

To study the lung ventilation impairment in asthma patients with obesity using capnometry. The tasks of the work are:

– to study parameters of lung ventilation in asthma patients and healthy persons;
– to compare the lung ventilation parameters in asthma patients depending on the presence of obesity.
Pulmonary function tests (body plethysmography and spirometry) were performed on the “Master Screen PFT” apparatus of the “Cardinal Health” company (Germany) according to the manufacturer’s methodology. The following parameters were studied:
- total resistance (Riot),
- total lung capacity (TLC),
- residual volume (RV),
- RV/TLC ratio,
- intrathoracic gas volume (ITGV),
- inspiratory capacity (IC),
- forced expiratory volume in the first second (FEV₁),
- forced vital capacity (FVC),
- FVC/FVC ratio,
- maximal expiratory flow at 75 %, 50 % and 25 % of remaining FVC (MEF₇₅/₄, MEF₅₀/₄, MEF₃₅/₄).

Capnometry was performed on a set for cardiorespiratory system examination “Oxycon Pro”, “Cardinal Health” (Germany), the following parameters were studied:
- volume of dead space (the volume of gases in non-perfused alveoli), ml (VD, ml),
- dead space to the tidal volume ratio % (VD%VT),
- minute ventilation (VE, l/min),
- alveolar ventilation (VA, l/min),
- end-tidal CO₂ pressure, (PETCO₂, kPa),
- end-tidal O₂ fraction (FETO₂, %).

The data collection and mathematical processing was carried out by licensed software products included in the Microsoft Office Professional 2007 package, Russian Academic OPEN 1 License No Level 43437596. Statistical analysis was performed using MS Excel with descriptive statistics (mean (M), the mean error (m)) and nonparametric statistics (Mann–Whitney test for two independent samples), the level of significance (P) was determined. Statistically significant differences were estimated at p-values of less than 0.05.

The study was agreed with the Ethics Committee of the NIPhP NAMS, all participants were acquainted with the study protocol and gave their written informed consent.

**Results**

Data on age, body weight and BMI of study participants are shown in Table 1.

 Anthropometric data, except for BMI, of the asthma patients did not differ from healthy subjects as healthy subjects were not obese. Accordingly, there were statistically significant differences only in body weight and BMI between asthma groups due to having obesity. 11 patients from 30 asthmatics were obese.

Based on the pulmonary function test results it was found that unlike healthy individuals, in asthma patients, all the parameters of body plethysmography and spirometry were abnormal, except for the TLC and IC, with the statistically significant difference (Table 2).

In determining the effect of obesity on the pulmonary function test in patients with asthma, we obtained evidence showing that lung volumes were reduced in patients with obesity. In particular, TLC, IC and FVC were reduced. At the same time, the severity of bronchial obstruction was more pronounced in obese patients compared with those without obesity.

Capnometry was performed for all 60 participants in the study. To solve the first task of our work, we analyzed the capnometry results in patients with asthma and healthy individuals. It was found that the overall pulmonary ventilation parameters in patients with asthma were slightly

**Table 1. Anthropometric data of the subjects (M ± m)**

| Indicators, units | Asthma patients, (n = 30) | Asthma patients with obesity, (n = 11) | Asthma patients without obesity, (n = 19) | Healthy subjects, (n = 30) |
|-------------------|--------------------------|--------------------------------------|------------------------------------------|---------------------------|
| Age, years        | 57.3 ± 2.3               | 60.3 ± 2.8                           | 55.5 ± 3.4                               | 48.7 ± 3.7                |
| Body weight, kg   | 79.6 ± 3.5               | 99.0 ± 4.2                           | 68.3 ± 2.5*                              | 78.5 ± 2.7                |
| BMI, kg/m²        | 28.7 ± 1.1               | 34.5 ± 1.4                           | 25.4 ± 0.7*                              | 24.2 ± 0.7*               |

*: statistically significant difference between asthma patients and healthy subjects, P < 0.05; #: statistically significant difference between asthma patients with and without obesity, P < 0.05.

**Table 2. Pulmonary function test results (M ± m)**

| Indicators, units | Asthma patients, (n = 30) | Asthma patients with obesity, (n = 11) | Asthma patients without obesity, (n = 19) | Healthy subjects, (n = 30) |
|-------------------|--------------------------|--------------------------------------|------------------------------------------|---------------------------|
| Riot, %           | 181.1 ± 13.4             | 180.3 ± 27.4                         | 181.5 ± 15.6                             | 91.2 ± 5.2#               |
| TLC, %            | 103.4 ± 2.8              | 96.3 ± 3.9                           | 107.7 ± 3.7*                             | 101.7 ± 2.8               |
| RV, %             | 128.7 ± 6.4              | 121.9 ± 13.4                         | 132.8 ± 6.8                              | 103.2 ± 5.1*              |
| RV/TLC, %         | 44.7 ± 1.4               | 44.8 ± 3.2                           | 44.6 ± 1.3                               | 32.5 ± 1.7*               |
| ITGV, %           | 106.7 ± 4.1              | 99.1 ± 8.1                           | 111.3 ± 4.5                              | 93.2 ± 4.4*               |
| IC, %             | 107.8 ± 4.2              | 101.1 ± 3.3                          | 111.6 ± 3.6*                             | 113.4 ± 3.5               |
| FEV₁, %           | 72.3 ± 1.8               | 67.8 ± 2.1                           | 74.9 ± 2.4*                              | 100.2 ± 1.5*              |
| FVC, %            | 93.9 ± 2.1               | 87.1 ± 2.3                           | 97.9 ± 2.7*                              | 102.4 ± 1.9*              |
| FEV₁/FVC, %       | 64.4 ± 1.6               | 65.1 ± 2.4                           | 64.0 ± 2.2                               | 81.6 ± 1.2*               |
| MEF₇₅/₄, %        | 52.3 ± 3.5               | 52.1 ± 7.1                           | 52.4 ± 4.1                               | 92.0 ± 3.2*               |
| MEF₅₀/₄, %        | 31.8 ± 2.1               | 30.3 ± 3.3                           | 32.7 ± 2.6                               | 88.7 ± 3.6*               |
| MEF₃₅/₄, %        | 22.5 ± 1.9               | 23.9 ± 3.3                           | 21.6 ± 2.3                               | 68.4 ± 5.9*               |

*: statistically significant difference between asthma patients and healthy subjects, P < 0.01; #: statistically significant difference between asthma patients with and without obesity, P < 0.05.
Оригинальные исследования

Table 3. Capnometry results (M ± m)

| Indicators, units | Asthma patients, (n = 30) | Asthma patients with obesity, (n = 11) | Asthma patients without obesity, (n = 19) | Healthy subjects, (n = 30) |
|-------------------|---------------------------|----------------------------------------|------------------------------------------|---------------------------|
| VE, L/min         | 10.7 ± 0.4                | 11.5 ± 0.8                             | 10.3 ± 0.4                               | 10.6 ± 0.3                |
| VD, ml            | 189 ± 8                   | 210.9 ± 15.0                           | 199.1 ± 11.9                            | 181 ± 8                  |
| VD%VT             | 27.4 ± 1.3                | 27.4 ± 1.8                             | 29.3 ± 1.6                              | 27.1 ± 1.2               |
| VA, L/min         | 7.8 ± 0.6                 | 8.2 ± 0.5                              | 7.4 ± 0.4                               | 7.9 ± 0.2                |
|PETCO₂, kPa        | 4.5 ± 0.1*                | 4.8 ± 0.1                              | 4.3 ± 0.1*                              | 4.6 ± 0.1               |
| FETO₂, %          | 15.7 ± 0.1               | 15.3 ± 0.2                            | 16.0 ± 0.2*                              | 15.5 ± 0.1             |

*: statistically significant difference between asthma patients and healthy subjects, P < 0.01;
#: statistically significant difference between asthma patients with and without obesity, P < 0.05.

Discussion

The obtained results of the pulmonary function tests correspond to the generally accepted data that in obesity, the TLC decreases due to an increased pressure in the abdominal cavity impeding the normal diaphragm excursion. Another TLC reduction mechanism is an excessive fat deposition in the thoracic cavity, which reduces the space for complete lung expansion during inhalation. The same mechanism is suggested for the decrease in IC [9]. In our study, a more pronounced bronchial obstruction was in obese asthmatics with FEV₁, 67.8 ± 2.1 % compared to those without obesity 74.9 ± 2.4 %, P < 0.05 that can be explained by a higher degree of bronchial hyperreactivity in BA-obesity phenotype [10]. The literature indicates that even obese non-asthmatics may have a significant airway obstruction due to small airway collapse when lung volume is reduced [11].

A similar mechanism underlies a higher PETCO₂ in obesity. An accumulation of carbon dioxide in the alveolar space is associated with inadequate ventilation through mechanisms of lung volumes reduction, inhibition of neural respiratory drive, respiratory muscle weakness and ventilation-perfusion mismatch [12]. Given the fact that carbon dioxide easily dissolves in blood and penetrates biological membranes, the value of PETCO₂ in the ideal pulmonary diffusing capacity should correspond to the partial pressure of carbon dioxide in arterial blood [13]. Although the level of PETCO₂ in the examined patients 4.8 ± 0.1 kPa did not exceed the normal values for this indicator (4.0–5.7 kPa) [14], but it was significantly higher than that in patients without obesity – 4.3 ± 0.1 kPa, P < 0.05, indicating the compromised processes of pulmonary ventilation with a tendency to accumulate carbon dioxide in these patients.

Regarding the FETO₂, it can be calculated from inspired atmospheric oxygen concentration of 20.85 % and expired oxygen concentration of 16.0 % by a non-obese asthma patient, so oxygen absorbance from the atmosphere is 4.85 %. Similarly, we assume that if expired oxygen concentration is 15.3 % in obese asthmatics, that is oxygen absorbance is 5.55 %, which is 14 % higher compared to patients without obesity.

According to the literature data, body weight gain causes an increased total oxygen demand. The research results show that oxygen consumption in obese patients at rest is 25 % higher than in patients with normal body weight. Metabolism in overweight individuals requires higher lung ventilation both for oxygen supply to tissues and carbon dioxide elimination [11]. In our study, oxygen consumption in obese patients was not as high as in the sources mentioned. We explain this difference by the fact that in our case, asthma patients with bronchial obstruction were studied rather than obese non-asthmatics.

Despite the lack of pharmacological strategies for a specific treatment of obese asthmatics, weight loss strategies have been thoroughly investigated and shown to be effective in improving respiratory health in these patients [15]. Thus, obesity is a current problem of clinical practice which significantly disrupts overall health of patients and complicates the course of BA, in particular [16].

Conclusions

1. Asthma patients with obesity have characteristics that include reduced total lung capacity, inspiratory capacity and forced vital capacity with a higher degree of airways obstruction.
2. These changes lead to lung ventilation impairment with a tendency to carbon dioxide retention, which may be an unfavorable factor for the process of gas exchange with increased oxygen demands for the entire organism in obesity.

Prospects for further research. Capnometry diagnostics criteria development for non-invasive hypercapnia detection in obese asthma patients for initial assessment prior to therapy and control evaluation of treatment efficacy.
Information about authors:
Feschenko Yu. I., MD, PhD, Dsc, Professor, Academician of NAMS of Ukraine, Director of SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0002-8650-0289
Gumeniuk G. L., MD, PhD, Dsc, Professor of the Department of Phthisiology and Pulmonology, National Medical Academy of Postgraduate Education named after P. L. Shupyk, Senior Researcher of the Department of Diagnosis, Therapy and Clinical Pharmacology of Lung Diseases, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0001-8160-7856
Gumeniuk M. I., MD, PhD, Dsc, Leading Researcher of the Department of Technologies in Treatment of Nonspecific Lung Diseases, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0002-4365-6224
Rekalova O. M., MD, PhD, DSc, Professor, Head of the Laboratory of Clinical Immunology, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0002-4631-2048

Information about authors:
Feschenko Yu. I., Academician NAMS Ukraine, Dr méd. sci. Professor, Director of the Institute of Infectious Diseases and Pneumology named after F. H. Yanovsky NAMS of Ukraine, Kyiv. ORCID ID: 0000-0002-9276-0490
Gumeniuk G. L., Dr méd. sci., Professor of the Department of Infectious Diseases and Pulmonology, National Medical Academy of Postgraduate Education named after P. L. Shupyk, Senior Researcher of the Department of Diagnosis, Therapy and Clinical Pharmacology of Lung Diseases, SI “National Institute of Infectious Diseases and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0001-5803-2986
Gumeniuk M. I., Dr méd. sci., PhD, DSc, Senior Researcher, Head of the Laboratory of Clinical Immunology, SI “National Institute of Infectious Diseases and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0002-8650-0289
Rekalova O. M., Dr méd. sci., MD, PhD, DSc, Professor, Head of the Laboratory of Clinical Immunology, SI “National Institute of Infectious Diseases and Pulmonology named after F. H. Yanovsky NAMS of Ukraine”, Kyiv. ORCID ID: 0000-0002-4365-6224

Conflicts of interest: authors have no conflict of interest to declare.

Відомості про авторів:
Фесченко Ю. І., академік НАМН України, д-р мед. наук, професор, директор ДУ “Національний інститут фтизиатрії і пульмонології імені Ф. Г. Яновського НАМН України”, м. Київ.
Гуменік Г. Л., д-р мед. наук, професор каф. фтизиатрії і пульмонології, Национальна медична академія післядипломного освіти імені П. Л. Шупика, старший науковий співробітник, ДУ «Національний інститут фтизіатрії і пульмонології імені Ф. Г. Яновського НАМН України», м. Київ.
Заїков С. В., д-р мед. наук, професор каф. фтизиатрії і пульмонології, Національна медична академія післядипломного освіти імені П. Л. Шупика, старший науковий співробітник, ДУ «Національний інститут фтизіатрії і пульмонології імені Ф. Г. Яновського НАМН України», м. Київ.
Рекалова О. М., д-р мед. наук, старший науковий співробітник, зав. лабораторії клінічної імунології, ДУ “Національний інститут фтизиатрії і пульмонології імені Ф. Г. Яновського НАМН України”, м. Київ.

Opilak S. G., канд. мед. наук, старший науковий співробітник відделів діагностики, терапії та клінічної фармакології захворювань легень, ДУ “Національний інститут фтизиатрії і пульмонології імені Ф. Г. Яновського НАМН України”, м. Київ.

Sведения об авторах:
Фесцененко Ю. И., академик НАМН Украины, д-р мед. наук, профессор, директор института, ГУ-Национальный институт фтизиатрии и пульмонология имени Ф. Г. Яновского НАМН Украины, г. Киев.
Гуменюк Г. Л., д-р мед. наук, профессор каф. фтизиатрии и пульмонологии, Национальная медицинская академия последипломного образования имени П. Л. Шупика, старший научный сотрудник отделения диагностики и клинической фармакологии заболеваний легких, ГУ-Национальный институт фтизиатрии и пульмонология имени Ф. Г. Яновского НАМН Украины, г. Киев.
Заико С. В., д-р мед. наук, профессор каф. фтизиатрии и пульмонологии, Национальная медицинская академия последипломного образования имени П. Л. Шупика, г. Киев.
Рекалова О. М., д-р мед. наук, старший научный сотрудник, зав. лабораторией клинической иммунологии, ГУ-Національний інститут фтизіатрії і пульмонології імені Ф. Г. Яновського НАМН України, м. Київ.

Conflict of interest: authors have no conflict of interest to declare.

References
[1] Garcia-Ro, F., Alvarez-Puebla, M., Esteban-Gorjio, I., Barranco, P., & Olguin, J. (2019). Obesity and Asthma. Key Clinical Questions. Journal Of Investigational Allergology And Clinical Immunology, 29(4), 262-271. doi: 10.18176/jiaci.0316
[2] Feschenko, Yu. I., Bashina, L. A., & Spigh, G. (2014). Osobennosti bronhialnoi astmy u bolshykh s metabolicheskim sindrom [Bronchial asthma features in patients with metabolic syndrome]. Health of Ukraine, 2, 6-8. Retrieved from http://health ua.com/article/25871-obs obennosti-bronhialnoi-astmy-u-bolshykh-s-metabolicheskim-sindrom. [In Russian]
[3] GINA Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (2018). Retrieved from https://ginasthma.org/wp-content/uploads/2018/04/Gina-GINA-2018-report-tracked_v1.3.pdf.
[4] Grace, J., Mohan, A., & Lugogo, N. (2019). Obesity and adult asthma. Current Opinion In Pulmonary Medicine, 25(1), 44-50. doi: 10.1097/ mcp.0000000000000531
[5] Peters, U., Dixon, A., & Forno, E. (2018). Obesity and asthma. Journal Of Allergy And Clinical Immunology, 141(4), 1169-1179. doi: 10.1016/j. jaci.2018.02.004
[6] Mohanan, S., Tapp, H., McWilliams, A., & Dulin, M. (2014). Obesity and asthma: Pathophysiology and implications for diagnosis and management in primary care. Experimental Biology And Medicine, 239(11), 1531-1540. doi: 10.1177/1537370214525302
[7] Opimakh, S. H. (2014). Otznaka leheveno ventilyatsii u lkontrolovannym perebihom [Lung ventilation evaluation in patients with uncontrolled asthma]. Asthma and allergy, 1, 13-17. [In Ukrainian].
[8] (2013). Pro zatverzhdennia ta provadzhennia medyko-tekhnolo chnych dokumentiv zi standartyzatsii medychnoi dopomohy pry bronhialnoi astmi: nakaz MOZ Ukrainy vid 08.10.2013 roku №868. [On approval and implementation of medical technology documents on standardization of medical care in bronchial asthma: order of the Ministry of Health of Ukraine from October 08, 2013 №868]. Retrieved from https://zakon rada.gov.ua/rada/show/voi868202-13?lang=uk. [In Ukrainian].
[9] Melo, L., Silva, M., & Calles, A. (2014). Obesity and lung function: a systematic review. Einstein (São Paulo), 12(1), 120-125. doi: 10.1590/ s1518-45902014v12n1;2891
[10] Bates, J. (2016). Physiological Mechanisms of Airway Hyperresponsiveness in Obese Asthma. American Journal Of Respiratory Cell And Molecular Biology, 54(5), 618-623. doi: 10.1165/rmcb.2016-0019p4
[11] Gomez-Llorente, M., Romero, R., Chueca, N., Martinez-Cañavate, A., & Gomez-Llorente, C. (2017). Obesity and Asthma: A Missing Link. International Journal Of Molecular Sciences, 18(7), 1490. doi: 10.3390/ijms18071490

[12] Egea-Santacollana, C., & Javaheri, S. (2016). Obesity Hypoventilation Syndrome. Current Sleep Medicine Reports, 2(1), 12-19. doi: 10.1007/s40675-016-0035-2

[13] Preiss, D., Azami, T., & Urman, R. (2015). Variations in Respiratory Excretion of Carbon Dioxide Can Be Used to Calculate Pulmonary Blood Flow. Journal Of Clinical Medicine Research, 7(2), 83-90. doi: 10.14740/jocmr1979w

[14] Herdy, A., Ritt, L., Stein, R., Araújo, C., Milani, M., & Meneghelo, R. et al. (2016). Cardiopulmonary Exercise Test: Background, Applicability and Interpretation. Arquivos Brasileiros De Cardiologia, 107(5), 467-481. doi: 10.5935/abc.20160171

[15] Baffi, C., Winnica, D., & Holguin, F. (2015). Asthma and obesity: mechanisms and clinical implications. Asthma Research And Practice, 1(1). doi: 10.1186/s40733-015-0001-7

[16] Tashiro, H., & Shore, S. (2019). Obesity and severe asthma. Allergology International, 68(2), 135-142. doi: 10.1016/j.aller.2018.10.004